scholarly journals Utilization of Magnetic-Activated Cell Sorting and High-Density Single Nucleotide Polymorphism Microarrays Improves Diagnostic Yield and Prognostic Value in Clinical Testing for Patients with Multiple Myeloma and Normal Routine Chromosome Study

2014 ◽  
Vol 132 (2) ◽  
pp. 233-236 ◽  
Author(s):  
Todd Christensen ◽  
Weiwen Deng ◽  
Bonnie McMahill ◽  
Joseph Schappert ◽  
Weihua Liu ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
Single Nucleotide Polymorphism ◽  
Cell Sorting ◽  
Prognostic Value ◽  
Diagnostic Yield ◽  
Chromosome Study ◽  
Clinical Testing ◽  
Nucleotide Polymorphism ◽  
Single Nucleotide ◽  
Magnetic Activated Cell Sorting

scholarly journals EP-2306: Prognostic value of PCI and single nucleotide polymorphism rs4803455 of TGFß1 gene in SCLC

2018 ◽  
Vol 127 ◽  
pp. S1272-S1273
Author(s):  
P. Ayala ◽  
J. Cacicedo ◽  
D. Delgado ◽  
J.M. Nieto-Guerrero ◽  
D. Herrero ◽  
...  
Keyword(s):  
Single Nucleotide Polymorphism ◽  
Prognostic Value ◽  
Nucleotide Polymorphism ◽  
Single Nucleotide

scholarly journals Sequence analysis of β-subunit genes of the 20S proteasome in patients with relapsed multiple myeloma treated with bortezomib or dexamethasone

Blood ◽  
2012 ◽  
Vol 120 (23) ◽  
pp. 4513-4516 ◽  
Author(s):  
David I. Lichter ◽  
Hadi Danaee ◽  
Michael D. Pickard ◽  
Olga Tayber ◽  
Michael Sintchak ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
Single Nucleotide Polymorphism ◽  
Proteasome Inhibitors ◽  
Proteasome Inhibition ◽  
Allelic Frequency ◽  
High Dose ◽  
20S Proteasome ◽  
Clinical Relapse ◽  
Nucleotide Polymorphism ◽  
Single Nucleotide

AbstractVariations within proteasome β (PSMB) genes, which encode the β subunits of the 20S proteasome, may affect proteasome function, assembly, and/or binding of proteasome inhibitors. To investigate the potential association between PSMB gene variants and treatment-emergent resistance to bortezomib and/or long-term outcomes, in the present study, PSMB gene sequence variation was characterized in tumor DNA samples from patients who participated in the phase 3 Assessment of Proteasome Inhibition for Extending Remissions (APEX) study of bortezomib versus high-dose dexamethasone for treatment of relapsed multiple myeloma. Twelve new PSMB variants were identified. No associations were found between PSMB single nucleotide polymorphism genotype frequency and clinical response to bortezomib or dexamethasone treatment or between PSMB single nucleotide polymorphism allelic frequency and pooled overall survival or time to progression. Although specific PSMB5 variants have been identified previously in preclinical models of bortezomib resistance, these variants were not detected in patient tumor samples collected after clinical relapse from bortezomib, which suggests that alternative mechanisms underlie bortezomib insensitivity. This study is registered at www.clinicaltrials.gov as NCT00048230.

scholarly journals A Single Nucleotide Polymorphism in SLC7A5 Was Associated With Clinical Response in Multiple Myeloma Patients

2018 ◽  
Vol 39 (1) ◽  
pp. 67-72 ◽  
Author(s):  
MING J. POI ◽  
JUNAN LI ◽  
JASMINE A. JOHNSON ◽  
YU KYOUNG CHO ◽  
DOUGLAS W. SBOROV ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
Single Nucleotide Polymorphism ◽  
Clinical Response ◽  
Nucleotide Polymorphism ◽  
Single Nucleotide

High Resolution Genomic Profiling Using Single Nucleotide Polymorphism Microarrays Identifies Multiple Novel Genomic Minimally Deleted Regions in Multiple Myeloma

Blood ◽  
2008 ◽  
Vol 112 (11) ◽  
pp. 625-625
Author(s):  
Brian A WalKer ◽  
Paola E Leone ◽  
Nicholas J Dickens ◽  
Matthew W Jenner ◽  
Laura Chiecchio ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
Single Nucleotide Polymorphism ◽  
High Resolution ◽  
Genomic Profiling ◽  
Nucleotide Polymorphism ◽  
Single Nucleotide
Sign in / Sign up

Export Citation Format

Share Document